Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 7/10

vs
industry
vs
history
Cash to Debt 0.16
RTIX's Cash to Debt is ranked lower than
90% of the 317 Companies
in the Global Medical Devices industry.

( Industry Median: 2.56 vs. RTIX: 0.16 )
Ranked among companies with meaningful Cash to Debt only.
RTIX' s 10-Year Cash to Debt Range
Min: 0.09  Med: 2.44 Max: N/A
Current: 0.16
Equity to Asset 0.45
RTIX's Equity to Asset is ranked lower than
76% of the 282 Companies
in the Global Medical Devices industry.

( Industry Median: 0.66 vs. RTIX: 0.45 )
Ranked among companies with meaningful Equity to Asset only.
RTIX' s 10-Year Equity to Asset Range
Min: 0.3  Med: 0.76 Max: 0.9
Current: 0.45
0.3
0.9
Interest Coverage 4.15
RTIX's Interest Coverage is ranked lower than
92% of the 165 Companies
in the Global Medical Devices industry.

( Industry Median: 10000.00 vs. RTIX: 4.15 )
Ranked among companies with meaningful Interest Coverage only.
RTIX' s 10-Year Interest Coverage Range
Min: 4.15  Med: 10.32 Max: 58.56
Current: 4.15
4.15
58.56
F-Score: 6
Z-Score: 1.50
M-Score: -2.48
WACC vs ROIC
17.08%
4.23%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 5/10

vs
industry
vs
history
Operating margin (%) 5.66
RTIX's Operating margin (%) is ranked higher than
59% of the 302 Companies
in the Global Medical Devices industry.

( Industry Median: 3.12 vs. RTIX: 5.66 )
Ranked among companies with meaningful Operating margin (%) only.
RTIX' s 10-Year Operating margin (%) Range
Min: -76.65  Med: -0.30 Max: 10.76
Current: 5.66
-76.65
10.76
Net-margin (%) 3.24
RTIX's Net-margin (%) is ranked higher than
54% of the 302 Companies
in the Global Medical Devices industry.

( Industry Median: 1.99 vs. RTIX: 3.24 )
Ranked among companies with meaningful Net-margin (%) only.
RTIX' s 10-Year Net-margin (%) Range
Min: -77.87  Med: -0.60 Max: 8.42
Current: 3.24
-77.87
8.42
ROE (%) 3.33
RTIX's ROE (%) is ranked higher than
51% of the 287 Companies
in the Global Medical Devices industry.

( Industry Median: 3.14 vs. RTIX: 3.33 )
Ranked among companies with meaningful ROE (%) only.
RTIX' s 10-Year ROE (%) Range
Min: -57.28  Med: -1.89 Max: 10.14
Current: 3.33
-57.28
10.14
ROA (%) 2.35
RTIX's ROA (%) is ranked higher than
57% of the 319 Companies
in the Global Medical Devices industry.

( Industry Median: -0.22 vs. RTIX: 2.35 )
Ranked among companies with meaningful ROA (%) only.
RTIX' s 10-Year ROA (%) Range
Min: -44.6  Med: -1.58 Max: 5.68
Current: 2.35
-44.6
5.68
ROC (Joel Greenblatt) (%) 7.55
RTIX's ROC (Joel Greenblatt) (%) is ranked higher than
54% of the 315 Companies
in the Global Medical Devices industry.

( Industry Median: 3.55 vs. RTIX: 7.55 )
Ranked among companies with meaningful ROC (Joel Greenblatt) (%) only.
RTIX' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -91.98  Med: -1.98 Max: 38.7
Current: 7.55
-91.98
38.7
Revenue Growth (3Y)(%) 14.80
RTIX's Revenue Growth (3Y)(%) is ranked higher than
84% of the 193 Companies
in the Global Medical Devices industry.

( Industry Median: 3.00 vs. RTIX: 14.80 )
Ranked among companies with meaningful Revenue Growth (3Y)(%) only.
RTIX' s 10-Year Revenue Growth (3Y)(%) Range
Min: -22.5  Med: 1.30 Max: 14.8
Current: 14.8
-22.5
14.8
EBITDA Growth (3Y)(%) 0.90
RTIX's EBITDA Growth (3Y)(%) is ranked lower than
52% of the 170 Companies
in the Global Medical Devices industry.

( Industry Median: 2.10 vs. RTIX: 0.90 )
Ranked among companies with meaningful EBITDA Growth (3Y)(%) only.
RTIX' s 10-Year EBITDA Growth (3Y)(%) Range
Min: -49  Med: -3.00 Max: 128.9
Current: 0.9
-49
128.9
» RTIX's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q2 2014

RTIX Guru Trades in Q2 2014

Chuck Royce 2,234,448 sh (-1.26%)
Jim Simons 26,600 sh (-70.01%)
» More
Q3 2014

RTIX Guru Trades in Q3 2014

Chuck Royce 1,907,948 sh (-14.61%)
Jim Simons 22,500 sh (-15.41%)
» More
Q4 2014

RTIX Guru Trades in Q4 2014

Jim Simons 24,500 sh (+8.89%)
Chuck Royce 1,789,548 sh (-6.21%)
» More
Q1 2015

RTIX Guru Trades in Q1 2015

Jim Simons 65,000 sh (+165.31%)
Chuck Royce 1,508,774 sh (-15.69%)
» More
» Details

Insider Trades

Latest Guru Trades with RTIX

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/E(ttm) 68.55
RTIX's P/E(ttm) is ranked lower than
82% of the 156 Companies
in the Global Medical Devices industry.

( Industry Median: 28.40 vs. RTIX: 68.55 )
Ranked among companies with meaningful P/E(ttm) only.
RTIX' s 10-Year P/E(ttm) Range
Min: 19.81  Med: 33.33 Max: 318.33
Current: 68.55
19.81
318.33
Forward P/E 29.41
RTIX's Forward P/E is ranked lower than
66% of the 96 Companies
in the Global Medical Devices industry.

( Industry Median: 23.26 vs. RTIX: 29.41 )
Ranked among companies with meaningful Forward P/E only.
N/A
PE(NRI) 67.10
RTIX's PE(NRI) is ranked lower than
82% of the 154 Companies
in the Global Medical Devices industry.

( Industry Median: 28.30 vs. RTIX: 67.10 )
Ranked among companies with meaningful PE(NRI) only.
RTIX' s 10-Year PE(NRI) Range
Min: 19.81  Med: 32.56 Max: 318.33
Current: 67.1
19.81
318.33
P/B 3.31
RTIX's P/B is ranked lower than
52% of the 287 Companies
in the Global Medical Devices industry.

( Industry Median: 3.11 vs. RTIX: 3.31 )
Ranked among companies with meaningful P/B only.
RTIX' s 10-Year P/B Range
Min: 0.27  Med: 1.41 Max: 3.35
Current: 3.31
0.27
3.35
P/S 1.44
RTIX's P/S is ranked higher than
71% of the 290 Companies
in the Global Medical Devices industry.

( Industry Median: 3.15 vs. RTIX: 1.44 )
Ranked among companies with meaningful P/S only.
RTIX' s 10-Year P/S Range
Min: 0.62  Med: 1.34 Max: 4.34
Current: 1.44
0.62
4.34
POCF 31.98
RTIX's POCF is ranked lower than
68% of the 149 Companies
in the Global Medical Devices industry.

( Industry Median: 21.63 vs. RTIX: 31.98 )
Ranked among companies with meaningful POCF only.
RTIX' s 10-Year POCF Range
Min: 3.56  Med: 31.45 Max: 237.8
Current: 31.98
3.56
237.8
EV-to-EBIT 32.91
RTIX's EV-to-EBIT is ranked lower than
68% of the 162 Companies
in the Global Medical Devices industry.

( Industry Median: 21.84 vs. RTIX: 32.91 )
Ranked among companies with meaningful EV-to-EBIT only.
RTIX' s 10-Year EV-to-EBIT Range
Min: -195.9  Med: -1.00 Max: 2390.3
Current: 32.91
-195.9
2390.3
Current Ratio 3.31
RTIX's Current Ratio is ranked higher than
57% of the 309 Companies
in the Global Medical Devices industry.

( Industry Median: 2.71 vs. RTIX: 3.31 )
Ranked among companies with meaningful Current Ratio only.
RTIX' s 10-Year Current Ratio Range
Min: 1  Med: 3.75 Max: 5.91
Current: 3.31
1
5.91
Quick Ratio 1.36
RTIX's Quick Ratio is ranked lower than
67% of the 309 Companies
in the Global Medical Devices industry.

( Industry Median: 2.03 vs. RTIX: 1.36 )
Ranked among companies with meaningful Quick Ratio only.
RTIX' s 10-Year Quick Ratio Range
Min: 0.49  Med: 1.68 Max: 3.07
Current: 1.36
0.49
3.07
Days Inventory 320.88
RTIX's Days Inventory is ranked lower than
86% of the 281 Companies
in the Global Medical Devices industry.

( Industry Median: 131.01 vs. RTIX: 320.88 )
Ranked among companies with meaningful Days Inventory only.
RTIX' s 10-Year Days Inventory Range
Min: 75.71  Med: 269.80 Max: 366.78
Current: 320.88
75.71
366.78
Days Sales Outstanding 53.60
RTIX's Days Sales Outstanding is ranked higher than
73% of the 273 Companies
in the Global Medical Devices industry.

( Industry Median: 68.21 vs. RTIX: 53.60 )
Ranked among companies with meaningful Days Sales Outstanding only.
RTIX' s 10-Year Days Sales Outstanding Range
Min: 28.72  Med: 44.52 Max: 81.26
Current: 53.6
28.72
81.26

Valuation & Return

vs
industry
vs
history
Price/Tangible Book 12.54
RTIX's Price/Tangible Book is ranked lower than
81% of the 261 Companies
in the Global Medical Devices industry.

( Industry Median: 4.35 vs. RTIX: 12.54 )
Ranked among companies with meaningful Price/Tangible Book only.
RTIX' s 10-Year Price/Tangible Book Range
Min: 0.97  Med: 2.52 Max: 10
Current: 12.54
0.97
10
Price/Projected FCF 2.50
RTIX's Price/Projected FCF is ranked lower than
60% of the 111 Companies
in the Global Medical Devices industry.

( Industry Median: 2.09 vs. RTIX: 2.50 )
Ranked among companies with meaningful Price/Projected FCF only.
RTIX' s 10-Year Price/Projected FCF Range
Min: 0.82  Med: 1.32 Max: 36.25
Current: 2.5
0.82
36.25
Price/Median PS Value 1.07
RTIX's Price/Median PS Value is ranked higher than
56% of the 263 Companies
in the Global Medical Devices industry.

( Industry Median: 1.14 vs. RTIX: 1.07 )
Ranked among companies with meaningful Price/Median PS Value only.
RTIX' s 10-Year Price/Median PS Value Range
Min: 0.65  Med: 1.11 Max: 3.07
Current: 1.07
0.65
3.07
Price/Graham Number 3.01
RTIX's Price/Graham Number is ranked lower than
59% of the 136 Companies
in the Global Medical Devices industry.

( Industry Median: 2.46 vs. RTIX: 3.01 )
Ranked among companies with meaningful Price/Graham Number only.
RTIX' s 10-Year Price/Graham Number Range
Min: 1.03  Med: 2.21 Max: 4.19
Current: 3.01
1.03
4.19
Earnings Yield (Greenblatt) (%) 3.06
RTIX's Earnings Yield (Greenblatt) (%) is ranked higher than
65% of the 308 Companies
in the Global Medical Devices industry.

( Industry Median: 0.60 vs. RTIX: 3.06 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) (%) only.
RTIX' s 10-Year Earnings Yield (Greenblatt) (%) Range
Min: 0.1  Med: 3.80 Max: 8.8
Current: 3.06
0.1
8.8

Business Description

Industry: Medical Devices » Medical Devices
Compare:MDT, SYK, SMA, ZMH, STJ » details
Traded in other countries:RT2.Germany,
RTI Surgical Inc, formerly RTI Biologics, Inc., was incorporated in 1997 in Florida as a wholly-owned subsidiary of the University of Florida Tissue Bank. The Company process donated human musculoskeletal and other tissue, including bone, cartilage, tendon, ligament, fascia lata, pericardium, sclera and dermal tissue, and bovine and porcine animal tissue in producing allograft and xenograft implants utilizing proprietary BIOCLEANSE, TUTOPLAST and CANCELLE SP sterilization processes and manufacture metal and synthetic implants for distribution to hospitals and surgeons. The Company process tissue at two facilities in Alachua, Florida and one facility in Neunkirchen, Germany, and manufacture metal and synthetic implants in Marquette, Michigan and Greenville, North Carolina. The Company distributes its implants and services in all 50 states and in over 45 countries. Its lines of business are comprised primarily of six categories: spine, sports medicine, surgical specialties, bone graft substitutes and general orthopedic, dental and ortho fixation. It has developed and utilized in the United States the patented BioCleanse tissue sterilization process, which is an automated, pharmaceutical grade chemical sterilization process for musculoskeletal bone and certain soft tissue. The TUTOPLAST tissue sterilization process utilizes solvent dehydration and chemical inactivation to remove blood, lipids and extraneous materials, and inactivate viruses and break down RNA and DNA into fragments not capable of replication and disease transmission while preserving the biological and mechanical properties. DBM-based pastes and putties are sterilized through the CANCELLE SP process, which is designed to preserve protein activity. The Company's competitors in the conventional allograft market include the Musculoskeletal Transplant Foundation ("MTF"), AlloSource, LifeCell, Inc., a subsidiary of Kinetic Concepts Inc. and LifeNet. Among its competitors in precision machined allograft are MTF, LifeNet and AlloSource. Other companies who process and distribute allograft pastes include Medtronic, AlloSource, Integra, Wright and MTF. Companies who process and distribute xenograft tissue include Synovis, LifeCell, Cook Surgical and Medtronic. The Company considers its competitors in the metal and synthetic markets to include Alphatec, Globus Medical, Inc. (Globus), NuVasive, Inc. (NuVasive) and Orthofix. The Company is subject to federal, state and foreign laws and regulations.
» More Articles for RTIX

Headlines

Articles On GuruFocus.com
Regeneration Technologies Inc. Reports Operating Results (10-Q) Nov 08 2010 
Weekly CFO Buys Highlight: Bank Mutual Corp., Heelys Inc., GenMark Diagnostics Inc., Regeneration Te Sep 19 2010 
Weekly CFO Buys Highlight: GNMK, RTIX, BKOR, PTEK, CLDX Sep 12 2010 
Regeneration Technologies Inc. Reports Operating Results (10-Q) Aug 09 2010 
Regeneration Technologies Inc. Reports Operating Results (10-Q) May 05 2010 
Regeneration Technologies Inc. Reports Operating Results (10-Q) Nov 02 2009 
Regeneration Technologies Inc. Reports Operating Results (10-Q) Aug 04 2009 
RTI Biologics Announces 2009 Second Quarter Results Jul 30 2009 
Regeneration Technologies Inc. Reports Operating Results (10-Q) May 02 2009 
RTI Biologics Announces 2008 Fourth Quarter Earnings and Year End Earnings and Conference Call Feb 11 2009 

More From Other Websites
RTI Surgical tops Street 2Q forecasts Jul 30 2015
RTI Surgical tops Street 2Q forecasts Jul 30 2015
9:03 am RTI Surgical Correction: Beats by $0.01, beats on revs; guides Q3 ~in-line; raises low end... Jul 30 2015
RTI SURGICAL, INC. Files SEC form 8-K, Results of Operations and Financial Condition, Financial... Jul 30 2015
RTI Surgical™ Announces 2015 Second Quarter Results Jul 30 2015
RTI Surgical Schedules 2015 Second Quarter Earnings and Conference Call for July 30, 2015 Jul 23 2015
RTI Surgical Schedules 2015 Second Quarter Earnings and Conference Call for July 30, 2015 Jul 23 2015
Thermo Fisher Tops Q2 Earnings and Revenues, Guides Up - Analyst Blog Jul 22 2015
Accuray, RaySearch Laboratories Ink RayCare Agreement - Analyst Blog Jul 14 2015
RTI SURGICAL, INC. Files SEC form 8-K, Entry into a Material Definitive Agreement, Financial... Jul 02 2015
RTI Surgical: A Strong Buy on Solid Q1 Results, Raised View - Analyst Blog May 21 2015
Coverage initiated on RTI Surgical by Sidoti May 21 2015
RTI SURGICAL, INC. Financials May 08 2015
IDEXX Laboratories: Q1 Placements Impress, Yet View Down - Analyst Blog May 08 2015
10-Q for RTI Surgical, Inc. May 06 2015
RTI Surgical (RTIX) Jumps: Stock Adds 6.9% in Session - Tale of the Tape May 05 2015
RTI SURGICAL, INC. Files SEC form 10-Q, Quarterly Report May 04 2015
DexCom (DXCM) Q1 Loss Wider Than Expected; Shares Fall - Analyst Blog Apr 30 2015
IDEXX Laboratories Misses on Q1 Earnings, Cuts '15 View - Analyst Blog Apr 29 2015
Merge Healthcare Revenues Top, Earnings Rise Y/Y in Q1 - Analyst Blog Apr 29 2015

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
FEEDBACK